

**Fiona de Hemptinne**  
**Venture Partner, UCB Ventures**

Fiona de Hemptinne joined in March 2018, UCB Ventures, a €150 million strategic corporate venture fund which was set up to invest in innovative, longer term and higher risk opportunities beyond UCB's current focus areas. She is a board director at Medifin, a medical Imaging start-up since 2015 and at the financiere de Tubize since 2014. She is on the governors' body at the London Business School since 2015 and a member of their audit and risk committee.

Fiona joined UCB in 2014 in the development bone team as Bone commercial lead based in Slough and as Head of Europe for the Bone Patient Value Unit built the European country teams to prepare the launch of UCB-Amgen's anti-sclerostin, EVENITY.

She started her career in 2001 and worked in Business Development for GlaxoSmithKline, Biologicals, in Belgium. In 2002, she moved to the US and worked at McKinsey & Company, based in their New Jersey office, covering healthcare clients in the US and Europe. From 2006 to 2014, she had several leadership roles at Lilly UK, Northern Hub and Europe contributing to the launches, new indications and relaunches of several drugs across different therapeutic areas (Neurology, Cardiovascular, Osteoporosis and Immunology), working with alliance partners (BI, Daiichi Sankyo, J&J and GSK), managing patient support programs and leading changes through patent exclusivities and new models.

Fiona graduated with a MSc. in Management degree at the Solvay Business School (U.L.B) and an MBA from Harvard Business School. She is a Fulbright Scholar and a Recipient of Belgian American Education Foundation (BAEF) scholarship.

She is Belgian, lives in London with her husband and her four children.